Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241191 | 1.00 | GRIK1 (0.34) | GRIK1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL22993865 | 0.81 | GRIK1 (0.34) | GRIK1GRIK2 | |
| SCHEMBL15173030 | 0.81 | GRIK1 (0.34) | GRIK1GRIK2 | |
| SCHEMBL23011121 | 0.79 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL3248555 | 0.78 | GRIK1 (0.35) | GRIK1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL11592206 | 0.77 | SQLE (0.33) | GRIK1GRIK2 | |
| SCHEMBL11592208 | 0.77 | SQLE (0.33) | GRIK1GRIK2 | |
| SCHEMBL22993862 | 0.76 | GRIK1 (0.32) | GRIK1 | |
| SCHEMBL28367538 | 0.75 | GRIK1 (0.33) | GRIK1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL607401 | 0.74 | TSHR (0.35) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745658-B2 | Process for preparing tertiary alkyl esters of (meth)acrylic acid having at least 4 carbon atoms in the alkyl radical | BASF SE (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20090023947-A1 | PROCESS FOR PREPARING TERTIARY ALKYL ESTERS OF (METH) ACRYLIC ACID HAVING AT LEAST 4 CARBON ATOMS IN THE ALKYL RADICAL | BASF SE (DE) | 2009-01-22 | — | — | US | disclosed |
| EP-2017255-A1 | Method for manufacturing tertiary alkyl esters of (meth) acrylic acid with at least 4 carbon atoms in the alkyl | BASF SE (DE) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023947-A1 | PROCESS FOR PREPARING TERTIARY ALKYL ESTERS OF (METH) ACRYLIC ACID HAVING AT LEAST 4 CARBON ATOMS IN THE ALKYL RADICAL | ACSL3, ACSL1, ACSL4 | GRIK1 1618/4885ALDH1A1 74/4885LMNA 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.